risk sharing scheme

Views & Analysis

As a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new care infrastructure.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.